Improvements in Patient‐Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real‐World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Documenti analoghi

• Impact of Delay of Treatment With Disease‐Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  di: Philip J. Mease, et al.
  Pubblicazione: (2025)
• What Matters in Psoriatic Arthritis: A Comparison of Patient and Clinician Perspectives
  di: Philip J. Mease, et al.
  Pubblicazione: (2025)
• Characterization of Second‐Line Therapy After First JAK Inhibitor Use: Results From the CorEvitas Rheumatoid Arthritis Registry
  di: Joshua F. Baker, et al.
  Pubblicazione: (2025)
• Characteristics That Predict Psoriatic Arthritis by the Classification Criteria for Psoriatic Arthritis in Patients With Juvenile Idiopathic Arthritis 18 Years After Disease Onset
  di: Agnes Szentpetery, et al.
  Pubblicazione: (2024)
• What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients With Psoriasis?
  di: Shashank Cheemalavagu, et al.
  Pubblicazione: (2024)